View Older Stories
-
Stifel Downgrades Arcellx Inc. (ACLX) to Hold
-
Evercore ISI Downgrades Arcellx Inc. (ACLX) to In Line
-
H.C. Wainwright Downgrades Arcellx Inc. (ACLX) to Neutral
-
William Blair Downgrades Arcellx Inc. (ACLX) to Market Perform
-
Piper Sandler Downgrades Arcellx Inc. (ACLX) to Neutral
-
Raymond James on Legend Biotech Corp. (LEGN): 'Arcellx Takeout Indicates Legend is Hugely Undervalued'
-
Wells Fargo Downgrades Arcellx Inc. (ACLX) to Equal Weight
-
Baird Downgrades Arcellx Inc. (ACLX) to Neutral
-
Truist Securities Downgrades Arcellx Inc. (ACLX) to Hold
-
Rothschild Redburn Downgrades Arcellx Inc. (ACLX) to Neutral
-
Arcellx (ACLX) Reiterated at Buy by Stifel: Still 'a Core SMid-Cap Holding'
-
Arcellx presents data on anito-cel binder specificity at TANDEM meeting
-
Arcellx presents anito-cel research at 2026 Tandem Meetings
-
UBS Assumes Arcellx Inc. (ACLX) at Buy
-
Wells Fargo Starts Arcellx Inc. (ACLX) at Overweight
-
Arcellx (ACLX) call put ratio 1 call to 5.2 puts with a focus on May 40 puts
-
Stifel: 'We’re Buyers of ACLX Here'
-
Arcellx reports positive trial data for multiple myeloma treatment
-
Stifel Reiterates Buy Rating on Arcellx (ACLX): ASH Presentation Awaited
-
Guggenheim Defending on Arcellx Inc. (ACLX) Amid 17pct Drop
-
Arcellx stock falls after Kelonia reveals promising blood cancer data
-
Wolfe Research Starts Arcellx Inc. (ACLX) at Peerperform
-
Arcellx, Inc. (ACLX) Misses Q3 EPS by 3c
-
Arcellx Inc. (ACLX) PT Raised to $130 at Canaccord Genuity
-
Stifel Starts Arcellx Inc. (ACLX) at Buy
-
Cantor Fitzgerald Assumes Arcellx Inc. (ACLX) at Neutral
-
Arcellx Inc. (ACLX) PT Raised to $133 at Scotiabank
-
Piper Sandler Reiterates Overweight Rating on Arcellx Inc. (ACLX)
-
Citi Starts Arcellx Inc. (ACLX) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Arcellx Inc. (ACLX)
-
Arcellx, Inc. (ACLX) Misses Q1 EPS by 37c
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Arcellx (ACLX) Appoints Andrew Galligan and Kristin Myers to Its Board
-
Stifel Reiterates Buy Rating on Arcellx Inc. (ACLX)
-
Biotech outlook for 2025: Stifel
-
Stifel Highlights Iovanace Biotherapeutics (IOVA) as 'Top Pick' in Biotech's 2025 Outlook Note
-
Stifel Reiterates Buy Rating on Arcellx Inc. (ACLX) on Anito-Cel 'Best-in-Class' Potential
-
TD Cowen Reiterates Buy Rating on Arcellx Inc. (ACLX), Cites 'Best-in-Class' Potential for Anito-Cel
-
Arcellx Inc. (ACLX) PT Raised to $112 at BofA Securities
-
Arcellx Inc. (ACLX) PT Raised to $136 at Truist Securities
-
Arcellx Inc. (ACLX) PT Raised to $115 at Piper Sandler
-
Arcellx, Inc. (ACLX) Misses Q3 EPS by 14c
-
Piper Sandler Reiterates Overweight Rating on Arcellx Inc. (ACLX)
-
Arcellx Inc. (ACLX) PT Raised to $106 at Baird
-
Arcellx Inc. (ACLX) PT Raised to $95 at H.C. Wainwright
-
Arcellx Inc. (ACLX) PT Raised to $100 at BofA Securities
-
Arcellx (ACLX) to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma
-
Arcellx Inc. (ACLX) PT Raised to $120 at Evercore ISI
-
Arcellx Inc. (ACLX) PT Raised to $122 at Stifel
-
Redburn-Atlantic Starts Arcellx Inc. (ACLX) at Buy

